One intervention in ORIGIN compared the effect of another insulin glargine product, 100 units/mL, to standard care on major adverse cardiovascular outcomes in 12,537 participants 50 years of age with abnormal glucose levels [i.e., impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT)] or early type 2 diabetes mellitus and established cardiovascular (i.e., CV) disease or CV risk factors at baseline
Deep lines may begin to appear less prominent, and overall texture improves, giving the face a more lifted and rejuvenated appearance
However, both compounds theoretically support metabolic health through distinct pathways
TRIUMPH-4 Phase 3 trial Retatrutide and osteoarthritis outcomes
That delay doesn't reduce efficacy, but it shifts when patients feel their ADHD medication 'kick in,' often causing them to mistakenly increase their stimulant dose